Tyr238
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr238  -  MSH2 (human)

Site Information
DFSTkDIyQDLNRLL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 36121371

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 ) , lymphoma ( 1 ) , anaplastic large cell lymphoma ( 1 ) , T cell lymphoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
NPM-ALK (human) ( 1 )

Downstream Regulation
Effects of modification on MSH2:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
apoptosis, inhibited ( 1 )
Inhibit interaction with:
MSH6 (human) ( 1 )

References 

1

Bone KM, et al. (2015) NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair. Blood Cancer J 5, e311
25978431   Curated Info

2

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

3

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info